Skip to main content

5-Amino-1MQ vs Humanin

Both 5-Amino-1MQ and Humanin are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

5-Amino-1MQ

Evidence C+

5-Amino-1-Methylquinolinium

A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.

View full 5-Amino-1MQ profile →

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

Side-by-Side

Attribute5-Amino-1MQHumanin
Evidence GradeC+B
FDA StatusNot FDA-approved — small-molecule research compound (NNMT inhibitor)Not FDA-approved — mitochondrial-derived peptide research compound
Typical Dose50–150 mg orally daily (research-only)Research range: 0.5–1 mg subcutaneous (rare clinical use)
Clinics Indexed315
Categoriesfat-loss, longevitymitochondrial, longevity, neuroprotection

Key reported benefits — 5-Amino-1MQ

  • NNMT inhibition
  • Fat-mass reduction (preclinical)
  • Muscle stem-cell support

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons